Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes

Molecular Therapy : the Journal of the American Society of Gene Therapy
Gregory S ArnoldJeffrey S Bartlett

Abstract

The development of rationally designed targeted gene delivery vectors is an important focus for gene therapy. While genetic modification of AAV can produce vectors with modified tropism, incorporation of targeting peptides into the structural context of the AAV virion often results in loss of function or loss of virion integrity. To address this issue, we have developed a targeting system using metabolically biotinylated AAV. We generated serotype 1, 2, 3, 4, and 5 AAV capsids with small peptide insertions that are metabolically biotinylated in packaging cells during vector production by coexpression of the Escherichia coli BirA, biotin ligase, gene. Biotin moieties are exposed on the surface of assembled AAV particles and can interact with avidin. Metabolically biotinylated AAV vectors produced in this manner maintained endogenous titer and tissue tropism, could be purified on monomeric avidin resin, and could be retargeted to cells engineered to express an artificial avidin-biotin receptor. This technology provides not only a single platform for the purification of multiple AAV vector serotypes, but also a means for the development of multiple targeted AAV vectors utilizing a single capsid modification via straightforward avi...Continue Reading

References

Jul 1, 1977·The Journal of General Virology·F L GrahamR Nairn
May 15, 1988·Analytical Biochemistry·M Wilchek, E A Bayer
Oct 4, 1996·Science·J D AltmanM M Davis
Sep 2, 1999·Trends in Biochemical Sciences·A Chapman-Smith, J E Cronan
Feb 19, 2000·Gene Therapy·P E Monahan, R J Samulski
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·M B Parrott, M A Barry
Dec 22, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·H ChaoC E Walsh
Jun 16, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·M GrifmanM D Weitzman
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·S A NicklinA H Baker
Dec 14, 2001·The Journal of Biological Chemistry·Pauliina LehtolainenSeppo Ylä-Herttuala
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Guang-Ping GaoJames M Wilson
May 3, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Wenfang Shi, Jeffrey S Bartlett
Nov 20, 2003·Journal of Virological Methods·Richard H SmithRobert M Kotin
Feb 24, 2004·The Journal of Gene Medicine·Véronique BlouinAnna Salvetti
Nov 2, 2004·The Journal of Gene Medicine·Jean-Pierre LouboutinJames M Wilson
Mar 1, 2005·Nature Biotechnology·Zhong WangXiao Xiao

❮ Previous
Next ❯

Citations

May 27, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Brian R Schultz, Jeffrey S Chamberlain
Jul 24, 2008·Annual Review of Biomedical Engineering·David V SchafferKwang-il Lim
Oct 16, 2008·Clinical Microbiology Reviews·Shyam Daya, Kenneth I Berns
Apr 15, 2011·Gene Therapy·N Pulicherla, A Asokan
May 16, 2008·Human Gene Therapy·Minna U KaikkonenKari J Airenne
Jun 19, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Matthew D StachlerJeffrey S Bartlett
Mar 18, 2010·Expert Opinion on Drug Delivery·Hanna P LeschSeppo Ylä-Herttuala
Oct 17, 2015·Acta Biomaterialia·Ana Rey-Rico, Magali Cucchiarini
Aug 20, 2009·Biotechnology Progress·Guan-Yu ChenYu-Chen Hu
May 3, 2008·The Journal of Gene Medicine·Hildegard BüningMichael Hallek
Sep 10, 2014·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Caitlin M GuentherJunghae Suh
Jul 11, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhijian WuR Jude Samulski
Nov 26, 2015·Molecular Therapy. Methods & Clinical Development·Qiang WangJames M Wilson
Nov 10, 2018·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Maria Yanqing ChenJunghae Suh
Jul 4, 2007·Nature Reviews. Genetics·Reinhard WaehlerDavid T Curiel
Jul 7, 2007·Biotechnology and Bioengineering·Jae-Hyung JangDavid V Schaffer
Jun 24, 2011·Pharmazie in unserer Zeit·Tobias AbelHildegard Büning
Jan 1, 2015·Expert Opinion on Orphan Drugs·Eric Hastie, R Jude Samulski
Nov 6, 2015·American Journal of Physiology. Renal Physiology·Ankita Bachhawat JaykumarPablo A Ortiz
Feb 27, 2020·Journal of Clinical Medicine·Fabian BlancJing Wang
Feb 12, 2020·Nature Reviews. Genetics·Chengwen Li, R Jude Samulski
Feb 28, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kathleen BörnerDirk Grimm
Apr 25, 2021·Virology Journal·Rossana Colón-ThilletDaniel Stone
Jan 11, 2011·Analytical Chemistry·Johanna M NiersBakhos A Tannous
Jan 23, 2018·Bioconjugate Chemistry·Parisa Moghaddam-Taaheri, Amy J Karlsson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.